Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury

Free Radical Biology and Medicine

Volumn 51, Issue 9, 2011, Pages 1774-1788

  Mukhopadhyay, Partha ^a   Horváth, Béla ^a,c   Kechrid, Malek ^a   Tanchian, Galin ^a   Rajesh, Mohanraj ^a   Naura, Amarjit S ^b   Boulares, A Hamid ^b   Pacher, Pál ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cisplatin; Free radicals; Nephropathy; Poly(ADP ribose) polymerase

Indexed keywords

3 NITROTYROSINE; 5 AMINOISOQUINOLINE; CISPLATIN; CREATININE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 ACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DEATH; CELL INFILTRATION; CELL VIABILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; MALE; MOUSE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UREA NITROGEN BLOOD LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; CISPLATIN; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLY(ADP-RIBOSE) POLYMERASES;

EID: 80053602773     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2011.08.006     Document Type: Article

References (106)

1. F. Ries, and J. Klastersky Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity Am. J. Kidney Dis. 8 1986 368 379 (Pubitemid 17235084)
2. R.W. Schrier Cancer therapy and renal injury J. Clin. Invest. 110 2002 743 745
3. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 2005 307 320 (Pubitemid 41130944)
4. C.A. Davis, H.S. Nick, and A. Agarwal Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide J. Am. Soc. Nephrol. 12 2001 2683 2690 (Pubitemid 33115415)
5. P. Mukhopadhyay, M. Rajesh, H. Pan, V. Patel, B. Mukhopadhyay, S. Batkai, B. Gao, G. Hasko, and P. Pacher Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy Free Radic. Biol. Med. 48 2010 457 467
6. G. Ramesh, and W.B. Reeves TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity J. Clin. Invest. 110 2002 835 842
7. N. Pabla, and Z. Dong Cisplatin nephrotoxicity: mechanisms and renoprotective strategies Kidney Int. 73 2008 994 1007 (Pubitemid 351543900)
8. A. Peralta-Leal, J.M. Rodriguez-Vargas, R. Aguilar-Quesada, M.I. Rodriguez, J.L. Linares, M.R. de Almodovar, and F.J. Oliver PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases Free Radic. Biol. Med. 47 2009 13 26
9. L. Virag, and C. Szabo The therapeutic potential of poly(ADP-ribose) polymerase inhibitors Pharmacol. Rev. 54 2002 375 429
10. P. Jagtap, and C. Szabo Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors Nat. Rev. Drug Discov. 4 2005 421 440 (Pubitemid 40704125)
11. L. Liaudet, P. Pacher, J.G. Mabley, L. Virag, F.G. Soriano, G. Hasko, and C. Szabo Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation Am. J. Respir. Crit. Care Med. 165 2002 372 377 (Pubitemid 34118511)
12. F.G. Soriano, L. Liaudet, E. Szabo, L. Virag, J.G. Mabley, P. Pacher, and C. Szabo Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice Shock 17 2002 286 292
13. O.V. Evgenov, and L. Liaudet Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock Curr. Vasc. Pharmacol. 3 2005 293 299 (Pubitemid 40933051)
14. F.G. Soriano, P. Pacher, J. Mabley, L. Liaudet, and C. Szabo Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase Circ. Res. 89 2001 684 691 (Pubitemid 34627068)
15. S. Lupachyk, H. Shevalye, Y. Maksimchyk, V.R. Drel, and I.G. Obrosova PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function Free Radic. Biol. Med. 50 2011 1400 1409
16. H. Shevalye, Y. Maksimchyk, P. Watcho, and I.G. Obrosova Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease Biochim. Biophys. Acta 1802 2010 1020 1027
17. H. Shevalye, R. Stavniichuk, W. Xu, J. Zhang, S. Lupachyk, Y. Maksimchyk, V.R. Drel, E.Z. Floyd, B. Slusher, and I.G. Obrosova Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model Biochem. Pharmacol. 79 2010 1007 1014
18. V.R. Drel, W. Xu, J. Zhang, P.F. Kador, T.K. Ali, J. Shin, U. Julius, B. Slusher, A.B. El-Remessy, and I.G. Obrosova Poly(ADP-ribose)polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats Invest. Ophthalmol. Vis. Sci. 50 2009 1778 1790
19. I.G. Obrosova, W. Xu, V.V. Lyzogubov, O. Ilnytska, N. Mashtalir, I. Vareniuk, I.A. Pavlov, J. Zhang, B. Slusher, and V.R. Drel PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy Free Radic. Biol. Med. 44 2008 972 981 (Pubitemid 351318144)
20. P. Pacher, L. Liaudet, F.G. Soriano, J.G. Mabley, E. Szabo, and C. Szabo The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes Diabetes 51 2002 514 521 (Pubitemid 34764811)
21. P. Pacher, J.S. Beckman, and L. Liaudet Nitric oxide and peroxynitrite in health and disease Physiol. Rev. 87 2007 315 424 (Pubitemid 46217686)
22. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M.J. O'Connor, A. Ashworth, J. Carmichael, S.B. Kaye, J.H. Schellens, and J.S. de Bono Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 361 2009 123 134
23. J. O'Shaughnessy, C. Osborne, J.E. Pippen, M. Yoffe, D. Patt, C. Rocha, I.C. Koo, B.M. Sherman, and C. Bradley Iniparib plus chemotherapy in metastatic triple-negative breast cancer N. Engl. J. Med. 364 2011 205 214
24. Y. Drew, E.A. Mulligan, W.T. Vong, H.D. Thomas, S. Kahn, S. Kyle, A. Mukhopadhyay, G. Los, Z. Hostomsky, E.R. Plummer, R.J. Edmondson, and N.J. Curtin Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2 J. Natl. Cancer Inst. 103 2011 334 346
25. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, K.M. Bell-McGuinn, C. Scott, J.N. Weitzel, A. Oaknin, N. Loman, K. Lu, R.K. Schmutzler, U. Matulonis, M. Wickens, and A. Tutt Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
26. A. Tutt, M. Robson, J.E. Garber, S.M. Domchek, M.W. Audeh, J.N. Weitzel, M. Friedlander, B. Arun, N. Loman, R.K. Schmutzler, A. Wardley, G. Mitchell, H. Earl, M. Wickens, and J. Carmichael Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
27. P.C. Fong, T.A. Yap, D.S. Boss, C.P. Carden, M. Mergui-Roelvink, C. Gourley, J. De Greve, J. Lubinski, S. Shanley, C. Messiou, R. A'Hern, A. Tutt, A. Ashworth, J. Stone, J. Carmichael, J.H. Schellens, J.S. de Bono, and S.B. Kaye Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J. Clin. Oncol. 28 2010 2512 2519
28. S. Ganesan MYC, PARP1, and chemoresistance: BIN there, done that? Sci. Signal. 4 2011 pe15
29. S. Pyndiah, S. Tanida, K.M. Ahmed, E.K. Cassimere, C. Choe, and D. Sakamuro c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance Sci. Signal. 4 2011 ra19
30. K. Hastak, E. Alli, and J.M. Ford Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin Cancer Res. 70 2010 7970 7980
31. R.K. Tadagavadi, and W.B. Reeves Renal dendritic cells ameliorate nephrotoxic acute kidney injury J. Am. Soc. Nephrol. 21 2010 53 63
32. S. Lee, S.O. Moon, W. Kim, M.J. Sung, D.H. Kim, K.P. Kang, Y.B. Jang, J.E. Lee, K.Y. Jang, S.Y. Lee, and S.K. Park Protective role of L-2-oxothiazolidine-4-carboxylic acid in cisplatin-induced renal injury Nephrol. Dial. Transplant. 21 2006 2085 2095 (Pubitemid 44295033)
33. M. Liu, D.N. Grigoryev, M.T. Crow, M. Haas, M. Yamamoto, S.P. Reddy, and H. Rabb Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice Kidney Int. 76 2009 277 285
34. R.K. Tadagavadi, and W.B. Reeves Endogenous IL-10 attenuates cisplatin nephrotoxicity: role of dendritic cells J. Immunol. 185 2010 4904 4911
35. S. Bolisetty, A.M. Traylor, J. Kim, R. Joseph, K. Ricart, A. Landar, and A. Agarwal Heme oxygenase-1 inhibits renal tubular macroautophagy in acute kidney injury J. Am. Soc. Nephrol. 21 2010 1702 1712
36. C. Brooks, Q. Wei, S.G. Cho, and Z. Dong Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models J. Clin. Invest. 119 2009 1275 1285
37. A.G. Basnakian, E.O. Apostolov, X. Yin, M. Napirei, H.G. Mannherz, and S.V. Shah Cisplatin nephrotoxicity is mediated by deoxyribonuclease I J. Am. Soc. Nephrol. 16 2005 697 702 (Pubitemid 41725106)
38. X. Han, J. Yue, and R.W. Chesney Functional TauT protects against acute kidney injury J. Am. Soc. Nephrol. 20 2009 1323 1332
39. B. Zhang, G. Ramesh, S. Uematsu, S. Akira, and W.B. Reeves TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity J. Am. Soc. Nephrol. 19 2008 923 932
40. M. Liu, C.C. Chien, M. Burne-Taney, R.R. Molls, L.C. Racusen, R.B. Colvin, and H. Rabb A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity J. Am. Soc. Nephrol. 17 2006 765 774
41. K. Oumouna-Benachour, C.P. Hans, Y. Suzuki, A. Naura, R. Datta, S. Belmadani, K. Fallon, C. Woods, and A.H. Boulares Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death Circulation 115 2007 2442 2450 (Pubitemid 46717967)
42. P. Mukhopadhyay, B. Horvath, M. Rajesh, S. Matsumoto, K. Saito, S. Batkai, V. Patel, G. Tanchian, R.Y. Gao, B.F. Cravatt, G. Hasko, and P. Pacher Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury Free Radic. Biol. Med. 50 2011 179 195
43. P. Mukhopadhyay, M. Rajesh, G. Hasko, B.J. Hawkins, M. Madesh, and P. Pacher Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy Nat. Protoc. 2 2007 2295 2301 (Pubitemid 351565867)
44. M. Rajesh, P. Mukhopadhyay, S. Batkai, V. Patel, K. Saito, S. Matsumoto, Y. Kashiwaya, B. Horvath, B. Mukhopadhyay, L. Becker, G. Hasko, L. Liaudet, D.A. Wink, A. Veves, R. Mechoulam, and P. Pacher Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy J. Am. Coll. Cardiol. 56 2010 2115 2125
45. C. Szabo, and V.L. Dawson Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion Trends Pharmacol. Sci. 19 1998 287 298 (Pubitemid 28358088)
46. H.J. Forman, and D.A. Dickinson Introduction to serial reviews on 4-hydroxy-2-nonenal as a signaling molecule Free Radic. Biol. Med. 37 2004 594 596 (Pubitemid 38993507)
47. H.J. Forman, J.M. Fukuto, T. Miller, H. Zhang, A. Rinna, and S. Levy The chemistry of cell signaling by reactive oxygen and nitrogen species and 4-hydroxynonenal Arch. Biochem. Biophys. 477 2008 183 195
48. A. Valavanidis, T. Vlachogianni, and C. Fiotakis 8-Hydroxy-2′ -deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 27 2009 120 139
49. R.A. Floyd, J.J. Watson, P.K. Wong, D.H. Altmiller, and R.C. Rickard Hydroxyl free radical adduct of deoxyguanosine: sensitive detection and mechanisms of formation Free Radic. Res. Commun. 1 1986 163 172
50. R.A. Floyd, J.J. Watson, J. Harris, M. West, and P.K. Wong Formation of 8-hydroxydeoxyguanosine, hydroxyl free radical adduct of DNA in granulocytes exposed to the tumor promoter, tetradecanoylphorbolacetate Biochem. Biophys. Res. Commun. 137 1986 841 846 (Pubitemid 16044464)
51. R.A. Floyd The role of 8-hydroxyguanine in carcinogenesis Carcinogenesis 11 1990 1447 1450 (Pubitemid 20281454)
52. J.W. Park, and R.A. Floyd Lipid peroxidation products mediate the formation of 8-hydroxydeoxyguanosine in DNA Free Radic. Biol. Med. 12 1992 245 250
53. H.C. Birnboim, L. Maidt, T. Raynor, and R.A. Floyd 8- Hydroxydeoxyguanosine in DNA from TPA-stimulated human granulocytes Free Radic. Res. 20 1994 113 117 (Pubitemid 2051922)
54. J.P. Eiserich, S. Baldus, M.L. Brennan, W. Ma, C. Zhang, A. Tousson, L. Castro, A.J. Lusis, W.M. Nauseef, C.R. White, and B.A. Freeman Myeloperoxidase, a leukocyte-derived vascular NO oxidase Science 296 2002 2391 2394 (Pubitemid 34734213)
55. J.P. Eiserich, M. Hristova, C.E. Cross, A.D. Jones, B.A. Freeman, B. Halliwell, and A. van der Vliet Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils Nature 391 1998 393 397 (Pubitemid 28093514)
56. A. van der Vliet, J.P. Eiserich, H. Kaur, C.E. Cross, and B. Halliwell Nitrotyrosine as biomarker for reactive nitrogen species Methods Enzymol. 269 1996 175 184 (Pubitemid 26295706)
57. F.J. Schopfer, P.R. Baker, and B.A. Freeman NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem. Sci. 28 2003 646 654 (Pubitemid 37500899)
58. C. Szabo, H. Ischiropoulos, and R. Radi Peroxynitrite: biochemistry, pathophysiology and development of therapeutics Nat. Rev. Drug Discov. 6 2007 662 680 (Pubitemid 47207751)
59. Y.D. Zheng, X.Q. Xu, F. Peng, J.Z. Yu, and H. Wu The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells Oncol. Rep. 25 2011 1399 1405
60. V. Kruse, S. Rottey, O. De Backer, S. Van Belle, V. Cocquyt, and H. Denys PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy Acta Clin. Belg. 66 2011 2 9
61. M. Rouleau, A. Patel, M.J. Hendzel, S.H. Kaufmann, and G.G. Poirier PARP inhibition: PARP1 and beyond Nat. Rev. Cancer 10 2010 293 301
62. H.J. Burstein Novel agents and future directions for refractory breast cancer Semin. Oncol. 38 Suppl. 2 2011 S17 S24
63. C. Underhill, M. Toulmonde, and H. Bonnefoi A review of PARP inhibitors: from bench to bedside Ann. Oncol. 22 2011 268 279
64. H. Calvert, and A. Azzariti The clinical development of inhibitors of poly(ADP-ribose) polymerase Ann. Oncol. 22 Suppl. 1 2011 i53 i59
65. G. Graziani, and C. Szabo Clinical perspectives of PARP inhibitors Pharmacol. Res. 52 2005 109 118 (Pubitemid 40725605)
66. C. Lewis, and J.A. Low Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer Curr. Opin. Investig. Drugs 8 2007 1051 1056 (Pubitemid 350224330)
67. A. Mangerich, and A. Burkle How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation Int. J. Cancer 128 2011 251 265
68. P. Mukhopadhyay, H. Pan, M. Rajesh, S. Batkai, V. Patel, J. Harvey-White, B. Mukhopadhyay, G. Hasko, B. Gao, K. Mackie, and P. Pacher CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model Br. J. Pharmacol. 160 2010 657 668
69. H. Pan, P. Mukhopadhyay, M. Rajesh, V. Patel, B. Mukhopadhyay, B. Gao, G. Hasko, and P. Pacher Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death J. Pharmacol. Exp. Ther. 328 2009 708 714
70. Guerrero-Beltran, C. E.; Mukhopadhyay, P.; Horvath, B.; Rajesh, M.; Tapia, E.; Garcia-Torres, I.; Pedraza-Chaverri, J.; Pacher, P. Sulforaphane, a natural constituent of broccoli, prevents cell death and inflammation in nephropathy. J. Nutr. Biochem. doi: 10.1016/j.jnutbio.2011.02.004.
71. H. Ischiropoulos, L. Zhu, and J.S. Beckman Peroxynitrite formation from macrophage-derived nitric oxide Arch. Biochem. Biophys. 298 1992 446 451
72. G. Ramesh, and W.B. Reeves Inflammatory cytokines in acute renal failure Kidney Int. Suppl. 91 2004 S56 S61
73. R. Radi, J.S. Beckman, K.M. Bush, and B.A. Freeman Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide Arch. Biochem. Biophys. 288 1991 481 487
74. Y. Wang, N.S. Kim, J.F. Haince, H.C. Kang, K.K. David, S.A. Andrabi, G.G. Poirier, V.L. Dawson, and T.M. Dawson Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos) Sci. Signal. 4 2011 ra20
75. K.K. David, S.A. Andrabi, T.M. Dawson, and V.L. Dawson Parthanatos, a messenger of death Front. Biosci. 14 2009 1116 1128
76. S.W. Yu, H. Wang, M.F. Poitras, C. Coombs, W.J. Bowers, H.J. Federoff, G.G. Poirier, T.M. Dawson, and V.L. Dawson Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor Science 297 2002 259 263 (Pubitemid 34761289)
77. S.W. Yu, S.A. Andrabi, H. Wang, N.S. Kim, G.G. Poirier, T.M. Dawson, and V.L. Dawson Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death Proc. Natl. Acad. Sci. U.S.A. 103 2006 18314 18319 (Pubitemid 44871655)
78. G. Szabo, S. Bahrle, N. Stumpf, K. Sonnenberg, E.E. Szabo, P. Pacher, T. Csont, R. Schulz, T.J. Dengler, L. Liaudet, P.G. Jagtap, G.J. Southan, C.F. Vahl, S. Hagl, and C. Szabo Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation Circ. Res. 90 2002 100 106 (Pubitemid 34074615)
79. G. Szabo, V. Buhmann, T. Andrasi, N. Stumpf, S. Bahrle, V. Kekesi, S. Hagl, C. Szabo, and A. Juhasz-Nagy Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest J. Thorac. Cardiovasc. Surg. 126 2003 651 658 (Pubitemid 37151946)
80. G. Szabo, L. Liaudet, S. Hagl, and C. Szabo Poly(ADP-ribose) polymerase activation in the reperfused myocardium Cardiovasc. Res. 61 2004 471 480 (Pubitemid 38210153)
81. G. Szabo, L. Seres, P. Soos, C. Flechtenmacher, Z. Zsengeller, F.U. Sack, C. Szabo, and S. Hagl Poly-ADP-ribose polymerase inhibition reduces mesenteric injury after cardiopulmonary bypass Thorac. Cardiovasc. Surg. 52 2004 338 343 (Pubitemid 40006722)
82. G. Szabo, P. Soos, U. Heger, C. Flechtenmacher, S. Bahrle, Z. Zsengeller, C. Szabo, and S. Hagl Poly(ADP-ribose) polymerase inhibition attenuates biventricular reperfusion injury after orthotopic heart transplantation Eur. J. Cardiothorac. Surg. 27 2005 226 234 (Pubitemid 40193131)
83. B. Zingarelli, A.L. Salzman, and C. Szabo Genetic disruption of poly(ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury Circ. Res. 83 1998 85 94 (Pubitemid 28322102)
84. C. Szabo Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications Pharmacol. Res. 52 2005 60 71 (Pubitemid 40725600)
85. L. Zheng, C. Szabo, and T.S. Kern Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB Diabetes 53 2004 2960 2967 (Pubitemid 39425922)
86. C. Szabo, A. Zanchi, K. Komjati, P. Pacher, A.S. Krolewski, W.C. Quist, F.W. LoGerfo, E.S. Horton, and A. Veves Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity Circulation 106 2002 2680 2686 (Pubitemid 35364922)
87. F. Garcia Soriano, L. Virag, P. Jagtap, E. Szabo, J.G. Mabley, L. Liaudet, A. Marton, D.G. Hoyt, K.G. Murthy, A.L. Salzman, G.J. Southan, and C. Szabo Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation Nat. Med. 7 2001 108 113 (Pubitemid 32095649)
88. C. Szabo, P. Pacher, Z. Zsengeller, A. Vaslin, K. Komjati, R. Benko, M. Chen, J.G. Mabley, and M. Kollai Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation Mol. Med. 10 2004 28 35 (Pubitemid 39440318)
89. C. Szabo, S. Cuzzocrea, B. Zingarelli, M. O'Connor, and A.L. Salzman Endothelial dysfunction in a rat model of endotoxic shock: importance of the activation of poly(ADP-ribose) synthetase by peroxynitrite J. Clin. Invest. 100 1997 723 735 (Pubitemid 27340522)
90. C. Szabo Potential role of the peroxynitrate-poly(ADP-ribose) synthetase pathway in a rat model of severe hemorrhagic shock Shock 9 1998 341 344 (Pubitemid 128463882)
91. A. Szabo, P. Hake, A.L. Salzman, and C. Szabo 3-Aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase, improves hemodynamics and prolongs survival in a porcine model of hemorrhagic shock Shock 10 1998 347 353 (Pubitemid 128463273)
92. C. Szabo, B. Zingarelli, and A.L. Salzman Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite Circ. Res. 78 1996 1051 1063 (Pubitemid 26168580)
93. P. Pacher, J.G. Mabley, F.G. Soriano, L. Liaudet, K. Komjati, and C. Szabo Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation Br. J. Pharmacol. 135 2002 1347 1350 (Pubitemid 34270904)
94. C.Y. Xiao, M. Chen, Z. Zsengeller, H. Li, L. Kiss, M. Kollai, and C. Szabo Poly(ADP-ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure J. Pharmacol. Exp. Ther. 312 2005 891 898 (Pubitemid 40293746)
95. P. Pacher, L. Liaudet, P. Bai, J.G. Mabley, P.M. Kaminski, L. Virag, A. Deb, E. Szabo, Z. Ungvari, M.S. Wolin, J.T. Groves, and C. Szabo Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction Circulation 107 2003 896 904 (Pubitemid 36241050)
96. P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, L. Liaudet, C. Szabo, and P. Pacher Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro Am. J. Physiol. Heart Circ. Physiol. 296 2009 H1466 H1483
97. P. Pacher, L. Liaudet, P. Bai, L. Virag, J.G. Mabley, G. Hasko, and C. Szabo Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure J. Pharmacol. Exp. Ther. 300 2002 862 867 (Pubitemid 34164989)
98. P. Pacher, L. Liaudet, J. Mabley, K. Komjati, and C. Szabo Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure J. Am. Coll. Cardiol. 40 2002 1006 1016 (Pubitemid 34994999)
99. P. Pacher, L. Liaudet, J.G. Mabley, A. Cziraki, G. Hasko, and C. Szabo Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure Int. J. Mol. Med. 17 2006 369 375
100. O. Szenczi, P. Kemecsei, M.F. Holthuijsen, N.A. van Riel, G.J. van der Vusse, P. Pacher, C. Szabo, M. Kollai, L. Ligeti, and T. Ivanics Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure Biochem. Pharmacol. 69 2005 725 732 (Pubitemid 40248615)
101. Bartha, E.; Solti, I.; Szabo, A.; Olah, G.; Magyar, K.; Szabados, E.; Kalai, T.; Hideg, K.; Toth, K.; Gero, D.; Szabo, C.; Sumegi, B.; Halmosi, R. Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure. J. Cardiovasc. Pharmacol. doi: 10.1097/FJC.0b013e318225c21e.
102. J.A. Munoz-Gamez, R. Quiles-Perez, A. Ruiz-Extremera, A.B. Martin-Alvarez, L. Sanjuan-Nunez, A. Carazo, J. Leon, F.J. Oliver, and J. Salmeron Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells Cancer Lett. 301 2011 47 56
103. M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Godlewski, G. Hasko, L. Liaudet, and P. Pacher Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis Biochem. Biophys. Res. Commun. 350 2006 352 357 (Pubitemid 44498642)
104. M. Rajesh, P. Mukhopadhyay, G. Godlewski, S. Batkai, G. Hasko, L. Liaudet, and P. Pacher Poly(ADP-ribose)polymerase inhibition decreases angiogenesis Biochem. Biophys. Res. Commun. 350 2006 1056 1062 (Pubitemid 44584200)
105. L. Tentori, P.M. Lacal, A. Muzi, A.S. Dorio, C. Leonetti, M. Scarsella, F. Ruffini, W. Xu, W. Min, A. Stoppacciaro, C. Colarossi, Z.Q. Wang, J. Zhang, and G. Graziani Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis Eur. J. Cancer 43 2007 2124 2133 (Pubitemid 47380363)
106. A. Pyriochou, G. Olah, E.A. Deitch, C. Szabo, and A. Papapetropoulos Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34 Int. J. Mol. Med. 22 2008 113 118